Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean

Authors: Clarisse Joachim, Jacqueline Veronique-Baudin, Stephen Ulric-Gervaise, Jonathan Macni, Thierry Almont, Olivier Pierre-Louis, Lidvine Godaert, Moustapha Drame, Jean-Luc Novella, Karim Farid, Vincent Vinh-Hung, Patrick Escarmant

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

The French West-Indies rank first for both prostate cancer incidence and mortality rates. Analyzing diagnostic and therapeutic procedures among patients with prostate cancer, using data from a population-based cancer registry, is essential for cancer surveillance and research strategies.

Methods

This retrospective observational cohort study was based on data from the Martinique Cancer Registry. Records of 452 patients diagnosed with prostate cancer in 2013 were retrieved from the registry. Data extracted were: socio-demographic and clinical characteristics, circumstances of diagnosis, PSA level at diagnosis, Gleason score and risk of disease progression. Stage at diagnosis and patterns of care among prostate cancer patients were analyzed.

Results

Mean age at diagnosis was 67 ± 8 years; 103 (28.5%) were symptomatic at diagnosis. Digital rectal exam was performed in 406 (93.8%). Clinical stage was available in 385 (85.2%); tumours were localized in 322/385 (83.6%). Overall, 17.9% were at low risk, 36.4% at intermediate and 31.9% at high risk; 13.8% were regional/metastatic cancers. Median PSA level at diagnosis was 8.16 ng/mL (range 1.4–5000 ng/mL). A total of 373 patients (82.5%) received at least one treatment, while 79 (17.5%) had active surveillance or watchful waiting. Among patients treated with more than one therapeutic strategy, the most frequent combination was external radiotherapy with androgen deprivation (n = 102, 22.6%).

Conclusions

This study provides detailed data regarding the quality of diagnosis and management of patients with prostate cancer in Martinique. Providing data on prostate cancer is essential for the development of high-priority public health measures for the Caribbean.
Literature
1.
go back to reference Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.CrossRef Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.CrossRef
2.
go back to reference Phillips AA, Jacobson JS, Magai C, Consedine N, Horowicz-Mehler NC, Neugut AI. Cancer incidence and mortality in the Caribbean. Cancer Investig. 2007;25(6):476–83.CrossRef Phillips AA, Jacobson JS, Magai C, Consedine N, Horowicz-Mehler NC, Neugut AI. Cancer incidence and mortality in the Caribbean. Cancer Investig. 2007;25(6):476–83.CrossRef
3.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRef
4.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
5.
go back to reference Bray F, Pineros M. Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud Publica Mex. 2016;58(2):104–17.CrossRef Bray F, Pineros M. Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud Publica Mex. 2016;58(2):104–17.CrossRef
6.
go back to reference Veronique-Baudin J, Dieye M, Kouyoumdjian JC, Vacheron F, Draganescu C, Azaloux H. Case-control study of the genes of receptors of the androgens of vitamin-D and of 5-alphareductase in a population of afro-Caribbean population with prostate cancer. Prog Urol. 2006;16(3):303–10.PubMed Veronique-Baudin J, Dieye M, Kouyoumdjian JC, Vacheron F, Draganescu C, Azaloux H. Case-control study of the genes of receptors of the androgens of vitamin-D and of 5-alphareductase in a population of afro-Caribbean population with prostate cancer. Prog Urol. 2006;16(3):303–10.PubMed
7.
go back to reference Cancel-Tassin G, Romana M, Gaffory C, Blanchet P, Cussenot O, Multigner L. Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). Asian J Androl. 2015;17(1):117–9.CrossRef Cancel-Tassin G, Romana M, Gaffory C, Blanchet P, Cussenot O, Multigner L. Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). Asian J Androl. 2015;17(1):117–9.CrossRef
8.
go back to reference Emeville E, Broquere C, Brureau L, Ferdinand S, Blanchet P, Multigner L, Romana M. Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in a Caribbean population of African descent. PLoS One. 2014;9(9):e107275.CrossRef Emeville E, Broquere C, Brureau L, Ferdinand S, Blanchet P, Multigner L, Romana M. Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in a Caribbean population of African descent. PLoS One. 2014;9(9):e107275.CrossRef
9.
go back to reference Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. 2017;123(12):2312–9.CrossRef Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. 2017;123(12):2312–9.CrossRef
10.
go back to reference Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet (London, England). 2012;380(9856):1840–50.CrossRef Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet (London, England). 2012;380(9856):1840–50.CrossRef
11.
go back to reference Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4(Suppl 1):S2.CrossRef Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4(Suppl 1):S2.CrossRef
12.
go back to reference Bouchardy C, Mirra AP, Khlat M, Parkin DM, de Souza JM, Gotlieb SL. Ethnicity and cancer risk in Sao Paulo, Brazil. Cancer Epidemiol Biomarkers Prev. 1991;1(1):21–7.PubMed Bouchardy C, Mirra AP, Khlat M, Parkin DM, de Souza JM, Gotlieb SL. Ethnicity and cancer risk in Sao Paulo, Brazil. Cancer Epidemiol Biomarkers Prev. 1991;1(1):21–7.PubMed
13.
go back to reference Best Plummer WS, Persaud P, Layne PJ. Ethnicity and cancer in Guyana, South America. Infect Agents Cancer. 2009;4(Suppl 1):S7.CrossRef Best Plummer WS, Persaud P, Layne PJ. Ethnicity and cancer in Guyana, South America. Infect Agents Cancer. 2009;4(Suppl 1):S7.CrossRef
14.
go back to reference Dieye M, Veronique-Baudin J, Draganescu C, Azaloux H. Cancer incidence in Martinique: a model of epidemiological transition. Eur J Cancer Prev. 2007;16(2):95–101.CrossRef Dieye M, Veronique-Baudin J, Draganescu C, Azaloux H. Cancer incidence in Martinique: a model of epidemiological transition. Eur J Cancer Prev. 2007;16(2):95–101.CrossRef
15.
go back to reference Registre Général des cancers de la Martinique. L’incidence et la mortalité par cancer en Martinique entre 2008 et 2012. Martinique: Données du Registre Général de la Martinique; 2016. Registre Général des cancers de la Martinique. L’incidence et la mortalité par cancer en Martinique entre 2008 et 2012. Martinique: Données du Registre Général de la Martinique; 2016.
17.
go back to reference Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England). 2018. https://doi.org/10.1016/S0140-6736(17)33326-3.CrossRef Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England). 2018. https://​doi.​org/​10.​1016/​S0140-6736(17)33326-3.CrossRef
18.
go back to reference Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, Payne H, Puts M, Zulian G, Balducci L, et al. Management of prostate Cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol. 2017;72(4):521–31.CrossRef Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, Payne H, Puts M, Zulian G, Balducci L, et al. Management of prostate Cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol. 2017;72(4):521–31.CrossRef
19.
go back to reference Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106(4):462–9.CrossRef Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010;106(4):462–9.CrossRef
20.
go back to reference Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15(9):e404–14.CrossRef Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15(9):e404–14.CrossRef
21.
go back to reference Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont G, Mongiat-Artus P, Ouzzane A, Ploussard G, Azria D, et al. CCAFU french national guidelines 2016-2018 on prostate cancer. Prog Urol. 2016;27(Suppl 1):S95–S143.CrossRef Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont G, Mongiat-Artus P, Ouzzane A, Ploussard G, Azria D, et al. CCAFU french national guidelines 2016-2018 on prostate cancer. Prog Urol. 2016;27(Suppl 1):S95–S143.CrossRef
22.
go back to reference Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.CrossRef Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.CrossRef
23.
go back to reference Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldana K, Ferreyra M, Debiasi M, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14(5):391–436.CrossRef Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldana K, Ferreyra M, Debiasi M, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013;14(5):391–436.CrossRef
24.
go back to reference Sierra MS, Soerjomataram I, Forman D. Prostate cancer burden in central and South America. Cancer Epidemiol. 2016;44(Suppl 1):S131–40.CrossRef Sierra MS, Soerjomataram I, Forman D. Prostate cancer burden in central and South America. Cancer Epidemiol. 2016;44(Suppl 1):S131–40.CrossRef
25.
go back to reference Glover FE Jr, Coffey DS, Douglas LL, Cadogan M, Russell H, Tulloch T, Baker TD, Wan RL, Walsh PC. The epidemiology of prostate cancer in Jamaica. J Urol. 1998;159(6):1984–6 discussion 1986-1987.CrossRef Glover FE Jr, Coffey DS, Douglas LL, Cadogan M, Russell H, Tulloch T, Baker TD, Wan RL, Walsh PC. The epidemiology of prostate cancer in Jamaica. J Urol. 1998;159(6):1984–6 discussion 1986-1987.CrossRef
26.
go back to reference Dieye M, Banydeen R, Macni J, Michel S, Veronique-Baudin J, Sasco A, Escarmant P, Joachim C. Geographic variations and temporal trends in prostate cancer in Martinique over a 25-year period. BMC Res Notes. 2014;7:262.CrossRef Dieye M, Banydeen R, Macni J, Michel S, Veronique-Baudin J, Sasco A, Escarmant P, Joachim C. Geographic variations and temporal trends in prostate cancer in Martinique over a 25-year period. BMC Res Notes. 2014;7:262.CrossRef
27.
go back to reference Alvarez YH, Yi ME, Garrote LF, Rodriguez RC. Incidence, mortality and survival from prostate cancer in Cuba, 1977-1999. Eur J Cancer Prev. 2004;13(5):377–81.CrossRef Alvarez YH, Yi ME, Garrote LF, Rodriguez RC. Incidence, mortality and survival from prostate cancer in Cuba, 1977-1999. Eur J Cancer Prev. 2004;13(5):377–81.CrossRef
28.
go back to reference Soto-Salgado M, Suarez E, Torres-Cintron M, Pettaway CA, Colon V, Ortiz AP. Prostate cancer incidence and mortality among Puerto Ricans: an updated analysis comparing men in Puerto Rico with US racial/ethnic groups. P R Health Sci J. 2012;31(3):107–13.PubMed Soto-Salgado M, Suarez E, Torres-Cintron M, Pettaway CA, Colon V, Ortiz AP. Prostate cancer incidence and mortality among Puerto Ricans: an updated analysis comparing men in Puerto Rico with US racial/ethnic groups. P R Health Sci J. 2012;31(3):107–13.PubMed
29.
go back to reference Gibson TN, Hanchard B, Waugh N, McNaughton D. Thirty-year trends in incidence and age-distribution of prostate cancer in Kingston and St Andrew, Jamaica, 1978-2007. West Indian Med J. 2011;60(1):9–12.PubMed Gibson TN, Hanchard B, Waugh N, McNaughton D. Thirty-year trends in incidence and age-distribution of prostate cancer in Kingston and St Andrew, Jamaica, 1978-2007. West Indian Med J. 2011;60(1):9–12.PubMed
30.
go back to reference Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer. 2006;6(8):603–12.CrossRef Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer. 2006;6(8):603–12.CrossRef
31.
go back to reference Armstrong BK. The role of the cancer registry in cancer control. Cancer Causes Control. 1992;3(6):569–79.CrossRef Armstrong BK. The role of the cancer registry in cancer control. Cancer Causes Control. 1992;3(6):569–79.CrossRef
32.
go back to reference Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading C. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.PubMed Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading C. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.PubMed
34.
go back to reference Jegu J, Tretarre B, Velten M, Guizard AV, Danzon A, Buemi A, Colonna M, Kadi-Hanifi AM, Ganry O, Molinie F, et al. Prostate cancer management and factors associated with radical prostatectomy in France in 2001. Prog Urol. 2010;20(1):56–64.CrossRef Jegu J, Tretarre B, Velten M, Guizard AV, Danzon A, Buemi A, Colonna M, Kadi-Hanifi AM, Ganry O, Molinie F, et al. Prostate cancer management and factors associated with radical prostatectomy in France in 2001. Prog Urol. 2010;20(1):56–64.CrossRef
35.
go back to reference Hosein I, Sukhraj R, Goetz L, Rambarran N, Persaud S. A Clinicopathological profile of prostate Cancer in Trinidad and Tobago. Adv Urol. 2016;2016:2075021.CrossRef Hosein I, Sukhraj R, Goetz L, Rambarran N, Persaud S. A Clinicopathological profile of prostate Cancer in Trinidad and Tobago. Adv Urol. 2016;2016:2075021.CrossRef
36.
go back to reference Atallah V, Leduc N, Creoff M, Sargos P, Taouil T, Escarmant P, Vinh-Hung V. Curative brachytherapy for prostate cancer in African-Caribbean patients: a retrospective analysis of 370 consecutive cases. Brachytherapy. 2017;16(2):342–7.CrossRef Atallah V, Leduc N, Creoff M, Sargos P, Taouil T, Escarmant P, Vinh-Hung V. Curative brachytherapy for prostate cancer in African-Caribbean patients: a retrospective analysis of 370 consecutive cases. Brachytherapy. 2017;16(2):342–7.CrossRef
37.
go back to reference Leduc N, Atallah V, Creoff M, Rabia N, Taouil T, Escarmant P, Vinh-Hung V. Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: a study of 274 African-Caribbean patients. Brachytherapy. 2015;14(6):826–33.CrossRef Leduc N, Atallah V, Creoff M, Rabia N, Taouil T, Escarmant P, Vinh-Hung V. Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: a study of 274 African-Caribbean patients. Brachytherapy. 2015;14(6):826–33.CrossRef
38.
go back to reference Meunier M, Eyraud R, Senechal C, Gourtaud G, Roux V, Lanchon C, Brureau L, Blanchet P. Active surveillance for favorable risk prostate Cancer in African Caribbean men: results of a prospective study. J Urol. 2017;197(5):1229–36.CrossRef Meunier M, Eyraud R, Senechal C, Gourtaud G, Roux V, Lanchon C, Brureau L, Blanchet P. Active surveillance for favorable risk prostate Cancer in African Caribbean men: results of a prospective study. J Urol. 2017;197(5):1229–36.CrossRef
39.
go back to reference Brureau L, Multigner L, Wallois A, Verhoest G, Ndong JR, Fofana M, Blanchet P. Prostate cancer in Guadeloupe (French West Indies): incidence, mortality and clinicopathological features. Bull Cancer. 2009;96(2):165–70.PubMed Brureau L, Multigner L, Wallois A, Verhoest G, Ndong JR, Fofana M, Blanchet P. Prostate cancer in Guadeloupe (French West Indies): incidence, mortality and clinicopathological features. Bull Cancer. 2009;96(2):165–70.PubMed
40.
go back to reference Mallick S, Blanchet P, Multigner L. Prostate cancer incidence in Guadeloupe, a French Caribbean archipelago. Eur Urol. 2005;47(6):769–72.CrossRef Mallick S, Blanchet P, Multigner L. Prostate cancer incidence in Guadeloupe, a French Caribbean archipelago. Eur Urol. 2005;47(6):769–72.CrossRef
41.
go back to reference Foahom Kamwa AD, Vian E, Agoua G, Senechal C, Bentaleb Y, Fofana M, Manip-M’ebobisse N, Blanchet P. Radiotherapy with androgen deprivation in high-risk prostate cancer: what outcomes on a Caribbean population? Prog Urol. 2012;22(15):954–62.CrossRef Foahom Kamwa AD, Vian E, Agoua G, Senechal C, Bentaleb Y, Fofana M, Manip-M’ebobisse N, Blanchet P. Radiotherapy with androgen deprivation in high-risk prostate cancer: what outcomes on a Caribbean population? Prog Urol. 2012;22(15):954–62.CrossRef
42.
go back to reference Loiselle A, Senechal C, Nevoux P, Benazzouz H, Bhakkan-Mambir B, Casenave J, Gourtaud G, Fofana M, Blanchet P. The significance of PSA density as predictive factor in afro-Caribbean patients eligible for active surveillance by the French protocol criteria. Prog Urol. 2014;24(6):327–33.CrossRef Loiselle A, Senechal C, Nevoux P, Benazzouz H, Bhakkan-Mambir B, Casenave J, Gourtaud G, Fofana M, Blanchet P. The significance of PSA density as predictive factor in afro-Caribbean patients eligible for active surveillance by the French protocol criteria. Prog Urol. 2014;24(6):327–33.CrossRef
43.
go back to reference Casenave J, Senechal C, Nevoux P, Gourtaud G, Tressieres B, Blanchet P. Stage IV prostate cancer in Guadeloupe, a French Caribbean archipelago. Prog Urol. 2014;24(3):167–72.CrossRef Casenave J, Senechal C, Nevoux P, Gourtaud G, Tressieres B, Blanchet P. Stage IV prostate cancer in Guadeloupe, a French Caribbean archipelago. Prog Urol. 2014;24(3):167–72.CrossRef
44.
go back to reference Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17.CrossRef Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17.CrossRef
45.
go back to reference Albertsen PC. When is active surveillance the appropriate treatment for prostate cancer? Acta Oncol (Stockholm, Sweden). 2011;50(Suppl 1):120–6.CrossRef Albertsen PC. When is active surveillance the appropriate treatment for prostate cancer? Acta Oncol (Stockholm, Sweden). 2011;50(Suppl 1):120–6.CrossRef
46.
go back to reference Soulie M, Grosclaude P, Villers A, Menegoz F, Schaffer P, Mace-Lesec'h J, Molinier L, Sauvage-Machelard M. A population-based study on management of prostate cancer in four regions of France. Prostate Cancer Prostatic Dis. 2001;4(3):154–60.CrossRef Soulie M, Grosclaude P, Villers A, Menegoz F, Schaffer P, Mace-Lesec'h J, Molinier L, Sauvage-Machelard M. A population-based study on management of prostate cancer in four regions of France. Prostate Cancer Prostatic Dis. 2001;4(3):154–60.CrossRef
47.
go back to reference Soulie M, Villers A, Grosclaude P, Menegoz F, Schaffer P, Mace-Lesec'h J, Sauvage-Machelard M, Grand A. A population-based study on radical prostatectomy in France. Prostate Cancer Prostatic Dis. 2001;4(2):118–23.CrossRef Soulie M, Villers A, Grosclaude P, Menegoz F, Schaffer P, Mace-Lesec'h J, Sauvage-Machelard M, Grand A. A population-based study on radical prostatectomy in France. Prostate Cancer Prostatic Dis. 2001;4(2):118–23.CrossRef
48.
go back to reference Gokce MI, Sundi D, Schaeffer E, Pettaway C. Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis. 2017;20(2):127–36.CrossRef Gokce MI, Sundi D, Schaeffer E, Pettaway C. Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review. Prostate Cancer Prostatic Dis. 2017;20(2):127–36.CrossRef
49.
go back to reference Silberstein JL, Feibus AH, Maddox MM, Abdel-Mageed AB, Moparty K, Thomas R, Sartor O. Active surveillance of prostate cancer in African American men. Urology. 2014;84(6):1255–61.CrossRef Silberstein JL, Feibus AH, Maddox MM, Abdel-Mageed AB, Moparty K, Thomas R, Sartor O. Active surveillance of prostate cancer in African American men. Urology. 2014;84(6):1255–61.CrossRef
50.
go back to reference Odom BD, Mir MC, Hughes S, Senechal C, Santy A, Eyraud R, Stephenson AJ, Ylitalo K, Miocinovic R. Active surveillance for low-risk prostate cancer in African American men: a multi-institutional experience. Urology. 2014;83(2):364–8.CrossRef Odom BD, Mir MC, Hughes S, Senechal C, Santy A, Eyraud R, Stephenson AJ, Ylitalo K, Miocinovic R. Active surveillance for low-risk prostate cancer in African American men: a multi-institutional experience. Urology. 2014;83(2):364–8.CrossRef
51.
go back to reference Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kubler H, Beer AJ, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate Cancer. J Urol. 2016;195(5):1436–43.CrossRef Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kubler H, Beer AJ, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate Cancer. J Urol. 2016;195(5):1436–43.CrossRef
Metadata
Title
Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean
Authors
Clarisse Joachim
Jacqueline Veronique-Baudin
Stephen Ulric-Gervaise
Jonathan Macni
Thierry Almont
Olivier Pierre-Louis
Lidvine Godaert
Moustapha Drame
Jean-Luc Novella
Karim Farid
Vincent Vinh-Hung
Patrick Escarmant
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-5047-5

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine